Posts

Esperion Therapeutics Acquired by Archimed in $1.1B Buyout Deal

on
Archimed agreed to acquire cardiovascular drug developer Esperion Therapeutics for $3.16 per share 1 The transaction closed on May 1, 2026 1 Archimed is a healthcare-focused investor acquiring Esperion and its portfolio of cardio drugs 2 The deal includes a potential contingent value right (CVR) sweetener for shareholders 1 Esperion shares surged following the acquisition announcement 2 Sources: 1. https://www.fiercepharma.com/pharma/healthcare-investor-archimed-pay-11b-take-esperion-and-its-roster-cardio-drugs-private 2. https://prismmarketview.com/esperion-shares-surge-on-1-1b-archimed-buyout-deal/

Amgen Abandons Cancer and Sjögren's Candidates Due to Weak Phase 2 Data

on

Deloitte's 15th Annual Report: Pharma R&D Returns Rise to 5.9% in 2024 Driven by GLP-1 Therapies

on

Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform at Keystone Symposia

on

Merck & Co.'s Keytruda Posts $8B in Q1 2026 as Qlex Picks Up Steam

on

Avalyn Pharma's Upsized $300M IPO Beats Expectations

on

Novartis Breaks Ground on Flagship North Carolina Manufacturing Hub as Key Milestone in $23B US Expansion

on

Corcept's Phase 2 DAZALS Study Shows Dazucorilant Provides 87% Reduction in Mortality Risk Over Two Years in ALS Patients

on

GSK and Alector Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart in Alzheimer's Disease

on

Avalyn Pharma Stock Surges 44% After Upsized $300M IPO

on

Komodo Health Promotes Paul Thomas to Chief Financial Officer

on

Recent US Approvals Advance Treatment for Chronic Spontaneous Urticaria (CSU)

on

Strengthening Payer Engagement with Real-World Evidence: Recent Developments

on